The selective estrogen receptor modulator DT56a (Femarelle) does not affect platelet reactivity in normal or thrombophilic postmenopausal women

Menopause

Volumn 18, Issue 3, 2011, Pages 285-288

  Nachtigall, Margaret J ^a   Jessel, Rebecca H ^a   Flaumenhaft, Robert ^b   Nachtigall, Richard ^a   Yoles, Israel ^c   Naftolin, Frederick ^a   Nachtigall, Lila E ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Clotting; DT56a; Femarelle; Hormone therapy; Menopause; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; DT 56A; FEMARELLE; PROTHROMBIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; FEMALE; GENE; GENE MUTATION; HETEROZYGOTE; HORMONAL THERAPY; HUMAN; POSTMENOPAUSE; PROTEIN S DEFICIENCY; RISK FACTOR; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOPHILIA;

ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; BLOOD PLATELETS; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; FACTOR V; FEMALE; HUMANS; MIDDLE AGED; MUTATION; PLANT EXTRACTS; POSTMENOPAUSE; PROTEIN S DEFICIENCY; PROTHROMBIN; SELECTIVE ESTROGEN RECEPTOR MODULATORS; THROMBOPHILIA;

EID: 79952183786     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e3181f2f01a     Document Type: Article

References (24)

1. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996;348:977-980. (Pubitemid 26340751)
2. Hoibraaten E, Abdelnoor M, Sandset PM. Hormone replacement therapy with estradiol and risk of venous thromboembolismVa population-based case-control study. Thromb Haemost 1999;82:1218-1221. (Pubitemid 29473780)
3. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333. (Pubitemid 34761611)
4. Zoller B, Dahlback B. Linkage between inherited resistance to activated protein C and factor V gene mutation in venous thrombosis. Lancet 1994;343:1536-1538. (Pubitemid 24180052)
5. Seligsohn U, Griffin J. Hereditary thrombophilia. In: Lichtman M, Beutler E, Kipps T, Kaushansky K, Prchal J, Seligsohn U, eds. Williams Hematology. New York, NY: McGraw-Hill, 2005:1688, 124, 89, 32.
6. Rosendaal FR, Vessey M, Rumley A, et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002;116:851-854. (Pubitemid 34227006)
7. Post MS, Rosing J, Van Der Mooren MJ, et al. Increased resistance to activated protein C after short-term oral hormone replacement therapy in healthy post-menopausal women. Br J Haematol 2002;119:1017-1023. (Pubitemid 35463828)
8. Wu O, Greer IA. Is screening for thrombophilia cost-effective? Curr Opin Hematol 2007;14:500-503. (Pubitemid 47457640)
9. Moro L, Reineri S, Piranda D, et al. Nongenomic effects of 17Aestradiol in human platelets: potentiation of thrombin-induced aggregation through estrogen receptor A and Src kinase. Blood 2005;105: 115-121. (Pubitemid 40053072)
10. Elkeles RS, Hampton JR, Mitchell JR. Effect of oestrogens on human platelet behaviour. Lancet 1968;2:315-318.
11. Yee DL, Bergeron AL, Sun CW, Dong JF, Bray PF. Platelet hyperreactivity generalizes to multiple forms of stimulation. J Thromb Haemost 2006;4:2043-2050. (Pubitemid 44226787)
12. Favaloro EJ. Clinical utility of the PFA-100. Semin Thromb Hemost 2008;34:709-733.
13. Yoles I, Yogev Y, Frenkel Y, Hirsch M, Nahum R, Kaplan B. Efficacy and safety of standard versus low-dose Femarelle (DT56a) for the treatment of menopausal symptoms. Clin Exp Obstet Gynecol 2004;31: 123-126. (Pubitemid 38833215)
14. Pluchino N, Merlini S, Cubeddu A, et al. Brain-region responsiveness to DT56a (Femarelle) administration on allopregnanolone and opioid content in ovariectomized rats. Menopause 2009;16:1037-1043.
15. Yoles I, Yogev Y, Frenkel Y, Nahum R, Hirsch M, Kaplan B. Tofupill/ Femarelle (DT56a): a new phyto-selective estrogen receptor modulatorlike substance for the treatment of postmenopausal bone loss. Menopause 2003;10:522-525. (Pubitemid 40228146)
16. Somjen D, Yoles I. DT56a (Tofupill/Femarelle) selectively stimulates creatine kinase specific activity in skeletal tissues of rats but not in the uterus. J Steroid Biochem Mol Biol 2003;86:93-98. (Pubitemid 37025753)
17. Somjen D, Katzburg S, Knoll E, et al. DT56a (Femarelle): a natural selective estrogen receptor modulator (SERM). J Steroid Biochem Mol Biol 2007;104:252-258. (Pubitemid 46891814)
18. Yoles I, Lilling G. Pharmacological doses of the natural phyto-SERM DT56a (Femarelle) have no effect on MCF-7 human breast cancer cellline. Eur J Obstet Gynecol Reprod Biol 2007;130:140-141. (Pubitemid 44918197)
19. Flaumenhaft R, Nachtigall M, Lowenstein J, Nachtigall L, Nachtigall R. Association of oral but not transdermal estrogen therapy with enhanced platelet reactivity in a subset of postmenopausal women. Menopause 2009;16:407-412.
20. Sestito A, Sciahbasi A, Landolfi R, Maseri A, Lanza GA, Andreotti F. A simple assay for platelet-mediated hemostasis in flowing whole blood (PFA-100): reproducibility and effects of sex and age. Cardiologia 1999;44:661-665.
21. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000;83:316-321. (Pubitemid 30093238)
22. Herrington DM, Vittinghoff E, Howard TD, et al. Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002;22: 1012-1017. (Pubitemid 34655232)
23. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-845. (Pubitemid 46294724)
24. Ganz PA, Land SR. Risks benefits and effects on quality of life of selective estrogen receptor modulator therapy in postmenopausal women at increased risk of breast cancer. Menopause 2008;15:797-803.